Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hexaminolevulinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8099497 | 0.89 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL8105421 | 0.89 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL10521274 | 0.89 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL10520894 | 0.89 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL7606203 | 0.89 | CYP1A2 (0.48) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL4073740 | 0.88 | CYP2C9 (0.49) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL721014 | 0.87 | DGKA (0.47) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL1177525 | 0.85 | HTR2C (0.44) | HTR2CCYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL6567273 | 0.84 | CYP2C9 (0.50) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 | |
| SCHEMBL10940388 | 0.83 | CYP1A2 (0.46) | HTR2CCYP1A2CYP2C9S1PR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8692014-B2 | Acid addition salts of 5-aminolevulinic acid or its derivatives | PHOTOCURE ASA (NO) | 2014-04-08 | — | — | US | disclosed |
| EP-1727786-B1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | PHOTOCURE ASA (NO) | 2011-06-29 | — | — | EP | disclosed |
| US-20110125012-A1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | BRAENDEN JON ERIK | 2011-05-26 | — | — | US | disclosed |
| EP-2308830-A1 | Acid addition salts of 5-aminolevulinic acid or its derivatives | Photocure ASA (NO) | 2011-04-13 | — | — | EP | disclosed |
| US-7888526-B2 | Nonhygroscopic photosensitizing agents; sulphonate, hydrobromide, sulfate, nitrate and/or phosphate derivatives; diagnosing skin disorders | PHOTOCURE ASA (NO) | 2011-02-15 | — | — | US | disclosed |
| US-20080064752-A1 | Acid Addition Salts Of-5-Aminolevulinic Acid Or Its Derivatives | PHOTOCURE ASA (NO) | 2008-03-13 | — | — | US | disclosed |
| EP-1727786-A1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | Photocure ASA (NO) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005092838-A1 | ACID ADDITION SALTS OF 5-AMINOLEVULINIC ACID OR ITS DERIVATIVES | PHOTOCURE ASA (NO) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064752-A1 | Acid Addition Salts Of-5-Aminolevulinic Acid Or Its Derivatives | ALAD, AASDHPPT, ABAT | HTR2C 2044/4885CYP1A2 1812/4885CYP2C9 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.